Why AptarGroup Stock Is Back On Investor Radars

AptarGroup (ATR) has drawn interest after recent share price moves, with the stock gaining about 6% over the past month while still showing a decline over the past year.

For investors tracking AptarGroup as a packaging and drug delivery supplier, those mixed return figures may prompt a closer look at how its current valuation lines up with recent business performance and market expectations.

With the share price at $120.32, AptarGroup has posted a 7 day share price return of 3.21% and a 30 day share price return of 5.91%. However, the 1 year total shareholder return has declined 18.47%, which suggests recent momentum contrasts with weaker long term outcomes.

If this kind of mixed performance has you reassessing your watchlist, it could be a good time to broaden your search through 20 top founder-led companies

So with AptarGroup trading at $120.32 and indicators like intrinsic value estimates and analyst targets suggesting a potential discount, should you see AptarGroup stock as undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 25.5% Undervalued

Based on the most followed narrative, AptarGroup stock trades below an estimated fair value of $161.43, compared with the current share price of $120.32, which raises questions about what assumptions sit behind that gap.

The rapid expansion of AptarGroup's proprietary drug delivery systems, particularly in injectables for biologics, GLP-1, and central nervous system therapies, positions the company to benefit from rising global healthcare needs and an aging population. These high-value platforms support future revenue growth and margin expansion.

Curious what kind of revenue path and profit profile underpin that valuation gap? The narrative leans on steady top line growth, resilient margins, and a richer future earnings multiple tied to these platforms.

Result: Fair Value of $161.43 (UNDERVALUED)

However, the AptarGroup narrative still faces pressure from higher legal costs tied to intellectual property disputes and uncertain demand for emergency medicine delivery systems like naloxone/Narcan.

Another View: What AptarGroup’s P/E Says About Valuation Risk

While AptarGroup looks undervalued on intrinsic value estimates, the picture shifts when you look at simple market ratios. The stock trades on a P/E of 19.9x, above the Global Packaging industry at 15.6x, the peer average at 16.3x, and the fair ratio estimate of 18.4x.

That richer P/E suggests the market already prices in a premium, which can limit upside if expectations ease or earnings progress slows. How comfortable are you paying more than both the sector and the fair ratio for AptarGroup today?

Next Steps

Given the mix of concerns and potential rewards around AptarGroup, are you ready to look past the headlines and examine the details yourself? To see how the balance of upside and downside stacks up, take a closer look at the 4 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond AptarGroup?

If you are serious about upgrading your portfolio, do not stop with AptarGroup. Use focused stock ideas to test your thinking and uncover fresh opportunities.

• Identify potential value by screening companies that pair quality fundamentals with attractive pricing through the 45 high quality undervalued stocks.
• Explore ways to strengthen your income stream by targeting reliable payers using the 8 dividend fortresses.
• Consider reducing portfolio stress by focusing on financially resilient businesses with the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.